| scholarly article | Q13442814 |
| P2093 | author name string | Laurent Verkoczy | |
| P2860 | cites work | Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation | Q80139485 |
| Auto-reactive B cells against peripheral antigen, desmoglein 3, escape from tolerance mechanism | Q80512517 | ||
| Censoring of autoreactive B cell development by the pre-B cell receptor | Q81485516 | ||
| Pathological roles of ganglioside mimicry in Guillain-Barré syndrome and related neuropathies | Q84207131 | ||
| Genome engineering using the CRISPR-Cas9 system | Q22122027 | ||
| Germinal center-associated nuclear protein (GANP) has a phosphorylation-dependent DNA-primase activity that is up-regulated in germinal center regions | Q24555214 | ||
| Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals | Q24635002 | ||
| Antibody-guided vaccine design: identification of protective epitopes | Q26747139 | ||
| HIV-Host Interactions: Implications for Vaccine Design | Q26765966 | ||
| Structural insights on the role of antibodies in HIV-1 vaccine and therapy | Q26829461 | ||
| A Blueprint for HIV Vaccine Discovery | Q26829865 | ||
| Antibody responses to envelope glycoproteins in HIV-1 infection | Q26991572 | ||
| HIV-1 neutralizing antibodies: understanding nature's pathways | Q27000480 | ||
| HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design | Q27022055 | ||
| Virological features associated with the development of broadly neutralizing antibodies to HIV-1 | Q27025177 | ||
| Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis | Q27489747 | ||
| Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors | Q27643993 | ||
| Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env | Q27644383 | ||
| Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody | Q27644415 | ||
| Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus | Q27644501 | ||
| Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies | Q27644515 | ||
| Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design | Q27644634 | ||
| Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1 | Q27662155 | ||
| Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 | Q27663293 | ||
| Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding | Q27670829 | ||
| Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing | Q27671696 | ||
| Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies | Q27674878 | ||
| A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield | Q27675032 | ||
| Broad and potent neutralization of HIV-1 by a gp41-specific human antibody | Q27675131 | ||
| Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2 | Q27675879 | ||
| Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors | Q27677104 | ||
| Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization | Q27677117 | ||
| Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16 | Q27678312 | ||
| An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. | Q37680009 | ||
| Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. | Q37702015 | ||
| Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice | Q37702078 | ||
| Using the emerging Collaborative Cross to probe the immune system | Q37731792 | ||
| Correlates of protection induced by vaccination | Q37750121 | ||
| Control systems and decision making for antibody production. | Q37774242 | ||
| Molecular mimicry as a mechanism of autoimmune disease | Q37957762 | ||
| Mechanisms of programmed DNA lesions and genomic instability in the immune system. | Q38078491 | ||
| Insights into B cells and HIV-specific B-cell responses in HIV-infected individuals | Q38114912 | ||
| Immune System Regulation in the Induction of Broadly Neutralizing HIV-1 Antibodies | Q38220506 | ||
| A bacterial lipooligosaccharide that naturally mimics the epitope of the HIV-neutralizing antibody 2G12 as a template for vaccine design. | Q38327409 | ||
| Sequence-Intrinsic Mechanisms that Target AID Mutational Outcomes on Antibody Genes | Q38388195 | ||
| Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential | Q38414485 | ||
| New approaches to HIV vaccine development | Q38521826 | ||
| Rheumatologic manifestations of infection with human immunodeficiency virus (HIV). | Q38656282 | ||
| HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies | Q38665463 | ||
| Selection of HIV vaccine candidates for concurrent testing in an efficacy trial | Q38716886 | ||
| Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires | Q38747466 | ||
| Humanized mice for HIV and AIDS research | Q38838864 | ||
| Approaches to the induction of HIV broadly neutralizing antibodies | Q38936867 | ||
| Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation | Q38959483 | ||
| Immunological Outcomes of Antibody Binding to Glycans Shared between Microorganisms and Mammals | Q39013747 | ||
| MK5 activates Rag transcription via Foxo1 in developing B cells | Q39121516 | ||
| HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes | Q39402539 | ||
| Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice | Q39407795 | ||
| Central tolerance regulates B cells reactive with Goodpasture antigen alpha3(IV)NC1 collagen | Q39926777 | ||
| Immune perturbations in HIV-1-infected individuals who make broadly neutralizing antibodies | Q40103798 | ||
| Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. | Q40290511 | ||
| Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. | Q40290521 | ||
| Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design | Q40296420 | ||
| T cell independent antigens | Q40404858 | ||
| Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. | Q40429324 | ||
| HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism. | Q40449984 | ||
| Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers. | Q40471380 | ||
| Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice | Q40589505 | ||
| Tolerance through indifference: autoreactive B cells to the nuclear antigen La show no evidence of tolerance in a transgenic model. | Q40614137 | ||
| Probing immune functions in RAG-deficient mice | Q40661080 | ||
| Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design | Q40679052 | ||
| False-positive human immunodeficiency virus testing in patients with lupus erythematosus | Q40777919 | ||
| Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate | Q41027647 | ||
| Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans. | Q41037927 | ||
| Analysis of gene function in lymphocytes by RAG-2-deficient blastocyst complementation. | Q41090386 | ||
| Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens | Q41170875 | ||
| Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. | Q41423746 | ||
| VARIATIONS IN AFFINITIES OF ANTIBODIES DURING THE IMMUNE RESPONSE | Q76969494 | ||
| Antigen drives very low affinity B cells to become plasmacytes and enter germinal centers | Q77573886 | ||
| Chronic graft-versus-host in Ig knockin transgenic mice abrogates B cell tolerance in anti-double-stranded DNA B cells | Q77892659 | ||
| Whole inactivated SIV virion vaccines with functional envelope glycoproteins: safety, immunogenicity, and activity against intrarectal challenge | Q78402662 | ||
| The PI3K p110delta is required for down-regulation of RAG expression in immature B cells | Q79717937 | ||
| Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies | Q27679353 | ||
| Autoreactivity and Exceptional CDR Plasticity (but Not Unusual Polyspecificity) Hinder Elicitation of the Anti-HIV Antibody 4E10 | Q27680125 | ||
| The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies | Q27680688 | ||
| Progress in HIV-1 vaccine development. | Q27693849 | ||
| PD-1 and its ligands in tolerance and immunity | Q28131650 | ||
| Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity | Q28138855 | ||
| Marginal-zone B cells | Q28201000 | ||
| The future of immune checkpoint therapy | Q28259862 | ||
| Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes | Q28271300 | ||
| GP120: target for neutralizing HIV-1 antibodies | Q28303124 | ||
| Potential role of molecular mimicry between Helicobacter pylori lipopolysaccharide and host Lewis blood group antigens in autoimmunity | Q28378893 | ||
| Altered pattern of immunoglobulin hypermutation in mice deficient in Slip-GC protein | Q28507678 | ||
| Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies | Q28602877 | ||
| HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers | Q28647225 | ||
| High-affinity IgG antibodies develop naturally in Ig-knockout rats carrying germline human IgH/Igκ/Igλ loci bearing the rat CH region | Q28709119 | ||
| Antibody neutralization and escape by HIV-1 | Q29547345 | ||
| Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 | ||
| Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors | Q29615065 | ||
| Broad neutralization coverage of HIV by multiple highly potent antibodies | Q29615361 | ||
| Immune-correlates analysis of an HIV-1 vaccine efficacy trial | Q29617377 | ||
| Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 | Q29619511 | ||
| Predominant autoantibody production by early human B cell precursors | Q29619656 | ||
| Recombinase-mediated cassette exchange (RMCE) — A rapidly-expanding toolbox for targeted genomic modifications | Q30039990 | ||
| Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans | Q30207889 | ||
| Affinity of antigen encounter and other early B-cell signals determine B-cell fate | Q30436993 | ||
| Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures | Q30746440 | ||
| Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data | Q31140424 | ||
| Anergy and not clonal ignorance determines the fate of B cells that recognize a physiological autoantigen | Q32024493 | ||
| Speckled-like pattern in the germinal center (SLIP-GC), a nuclear GTPase expressed in activation-induced deaminase-expressing lymphomas and germinal center B cells | Q33112697 | ||
| Foxo1 directly regulates the transcription of recombination-activating genes during B cell development | Q33333434 | ||
| Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers | Q33444658 | ||
| Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection | Q33479167 | ||
| Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance | Q33591736 | ||
| Optimality of mutation and selection in germinal centers | Q33598442 | ||
| Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection | Q33702217 | ||
| HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies | Q33753573 | ||
| Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope | Q34991017 | ||
| Polyreactivity and autoreactivity among HIV-1 antibodies | Q34992787 | ||
| The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection | Q35076717 | ||
| Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques | Q35101333 | ||
| Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies | Q35116581 | ||
| Crystal structure of the HIV neutralizing antibody 2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomannose | Q35119778 | ||
| Activation‐Induced Cytidine Deaminase Links Class Switch Recombination and Somatic Hypermutation | Q35119869 | ||
| Genetic analysis of complex traits in the emerging Collaborative Cross | Q35145475 | ||
| Different sensitivity to receptor editing of B cells from mice hemizygous or homozygous for targeted Ig transgenes | Q35160175 | ||
| HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development | Q35172770 | ||
| Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. | Q35192782 | ||
| A dynamic T cell-limited checkpoint regulates affinity-dependent B cell entry into the germinal center | Q35213561 | ||
| Rescue of HIV-1 broad neutralizing antibody-expressing B cells in 2F5 VH x VL knockin mice reveals multiple tolerance controls | Q35336374 | ||
| Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors | Q35382871 | ||
| DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers | Q35640984 | ||
| Antibody-based protection against HIV infection by vectored immunoprophylaxis | Q35658856 | ||
| Autoreactivity in human IgG+ memory B cells | Q35729131 | ||
| Germinal center-associated nuclear protein contributes to affinity maturation of B cell antigen receptor in T cell-dependent responses. | Q35731798 | ||
| HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes | Q35826271 | ||
| Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design | Q35868076 | ||
| The microRNA miR-148a functions as a critical regulator of B cell tolerance and autoimmunity. | Q35930798 | ||
| HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen | Q35969973 | ||
| Altered Ig hypermutation pattern and frequency in complementary mouse models of DNA polymerase ζ activity | Q35980902 | ||
| BLyS-mediated modulation of naive B cell subsets impacts HIV Env-induced antibody responses | Q36016522 | ||
| Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development | Q36041356 | ||
| Activin A programs the differentiation of human TFH cells | Q36067435 | ||
| Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design. | Q36112751 | ||
| Transgenic mice and analysis of B-cell tolerance | Q36135218 | ||
| Restricted VH gene usage and generation of antibody diversity in rabbit | Q36135235 | ||
| Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice | Q36159067 | ||
| Similarity and divergence in the development and expression of the mouse and human antibody repertoires | Q36220112 | ||
| Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequence-binding protein | Q36227838 | ||
| High affinity germinal center B cells are actively selected into the plasma cell compartment. | Q36228042 | ||
| Loss of the proapoptotic protein, Bim, breaks B cell anergy | Q36228387 | ||
| Antigen recognition strength regulates the choice between extrafollicular plasma cell and germinal center B cell differentiation | Q36228608 | ||
| Characteristics of the earliest cross-neutralizing antibody response to HIV-1. | Q33798076 | ||
| Redemption of autoreactive B cells | Q33835034 | ||
| Redemption of autoantibodies on anergic B cells by variable-region glycosylation and mutation away from self-reactivity. | Q33835200 | ||
| Autoantigen discovery with a synthetic human peptidome | Q33908182 | ||
| CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy | Q33937501 | ||
| Relative roles of somatic and Darwinian evolution in shaping the antibody response | Q33941984 | ||
| Modeling and optimization of populations subject to time-dependent mutation | Q33958359 | ||
| High-resolution description of antibody heavy-chain repertoires in humans | Q33988374 | ||
| Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies | Q34016211 | ||
| Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination | Q34022578 | ||
| Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines | Q34057711 | ||
| Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline | Q34075820 | ||
| Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies | Q34114798 | ||
| Tolerance to self gangliosides is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain-Barré syndrome | Q34129949 | ||
| AIDS/HIV. Host controls of HIV neutralizing antibodies | Q34170264 | ||
| Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies | Q34177732 | ||
| Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes | Q34270980 | ||
| B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study | Q34273373 | ||
| Broadly neutralizing antiviral antibodies | Q34323311 | ||
| Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies | Q34324992 | ||
| Immune clearance of highly pathogenic SIV infection | Q34370314 | ||
| Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs | Q34539819 | ||
| Induction of immunity to human immunodeficiency virus type-1 by vaccination | Q34540645 | ||
| miRNAs Are Essential for the Regulation of the PI3K/AKT/FOXO Pathway and Receptor Editing during B Cell Maturation | Q34545673 | ||
| Human immunodeficiency virus infection and systemic lupus erythematosus. An unusual case and a review of the literature | Q34566963 | ||
| The immune response during acute HIV-1 infection: clues for vaccine development | Q34614862 | ||
| B cell responses to HIV-1 infection and vaccination: pathways to preventing infection | Q34645502 | ||
| Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif. | Q34648342 | ||
| Mice transgenic for CD4-specific human CD4, CCR5 and cyclin T1 expression: a new model for investigating HIV-1 transmission and treatment efficacy | Q34730602 | ||
| Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles | Q34772727 | ||
| Structural evolution of glycan recognition by a family of potent HIV antibodies | Q34782382 | ||
| HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies. | Q34915786 | ||
| Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies | Q34982715 | ||
| In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire | Q41602128 | ||
| Reconstructing a B-cell clonal lineage. I. Statistical inference of unobserved ancestors | Q41818598 | ||
| In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. IV. Affinity-dependent, antigen-driven B cell apoptosis in germinal centers as a mechanism for maintaining self-tolerance | Q41888015 | ||
| CTCF-binding elements mediate control of V(D)J recombination | Q42145363 | ||
| Manipulating the selection forces during affinity maturation to generate cross-reactive HIV antibodies | Q42170932 | ||
| Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responses | Q42278743 | ||
| Strategies for selective priming of memory B cells | Q42577128 | ||
| Immunoglobulin signal transduction guides the specificity of B cell-T cell interactions and is blocked in tolerant self-reactive B cells | Q42942148 | ||
| Relaxed negative selection in germinal centers and impaired affinity maturation in bcl-xL transgenic mice | Q42947038 | ||
| Preferrential rearrangement in normal rabbits of the 3' VHa allotype gene that is deleted in Alicia mutants; somatic hypermutation/conversion may play a major role in generating the heterogeneity of rabbit heavy chain variable region sequences | Q43446985 | ||
| Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery. | Q43646588 | ||
| Breakdown of self-tolerance in anergic B lymphocytes. | Q43668436 | ||
| Unique signaling properties of B cell antigen receptor in mature and immature B cells: implications for tolerance and activation | Q43760103 | ||
| Editors and editing of anti-DNA receptors. | Q43832072 | ||
| Human antibody expression in transgenic rats: comparison of chimeric IgH loci with human VH, D and JH but bearing different rat C-gene regions | Q44182322 | ||
| Selection of Ig μ Heavy Chains by Complementarity-Determining Region 3 Length and Amino Acid Composition | Q44625268 | ||
| Generation of high-affinity antibody against T cell-dependent antigen in the Ganp gene-transgenic mouse | Q44992122 | ||
| Primary antibody-forming cells and secondary B cells are generated from separate precursor cell subpopulations. | Q45980652 | ||
| A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene | Q46098688 | ||
| Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. | Q46109491 | ||
| Antigen-induced B-cell death and elimination during germinal-centre immune responses | Q46147419 | ||
| Development of the expressed Ig CDR-H3 repertoire is marked by focusing of constraints in length, amino acid use, and charge that are first established in early B cell progenitors | Q46535428 | ||
| A single DH gene segment creates its own unique CDR-H3 repertoire and is sufficient for B cell development and immune function | Q46792429 | ||
| Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer | Q47372605 | ||
| The pre-B cell receptor: turning autoreactivity into self-defense | Q47398811 | ||
| Self-reactive B lymphocytes overexpressing Bcl-xL escape negative selection and are tolerized by clonal anergy and receptor editing. | Q47713262 | ||
| Memory B-cell persistence is independent of persisting immunizing antigen. | Q47821945 | ||
| A c-Myc/miR17-92/Pten Axis Controls PI3K-Mediated Positive and Negative Selection in B Cell Development and Reconstitutes CD19 Deficiency. | Q50502479 | ||
| Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. | Q51981842 | ||
| Soluble antigen can cause enhanced apoptosis of germinal-centre B cells. | Q52053087 | ||
| IgM heavy chain complementarity-determining region 3 diversity is constrained by genetic and somatic mechanisms until two months after birth. | Q52177381 | ||
| Frequent aberrant immunoglobulin gene rearrangements in pro-B cells revealed by a bcl-xL transgene. | Q52202641 | ||
| The site and stage of anti-DNA B-cell deletion. | Q52210540 | ||
| Somatic hypermutation in B cells: an optimal control treatment. | Q52390653 | ||
| Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. | Q53592113 | ||
| The Collaborative Cross, a community resource for the genetic analysis of complex traits | Q56896214 | ||
| The impact of T helper and T regulatory cells on the regulation of anti-double-stranded DNA B cells | Q56904544 | ||
| Systemic and discoid lupus erythematosus in HIV-infected patients treated with highly active antiretroviral therapy | Q57003999 | ||
| Structural vaccinology starts to deliver | Q57988219 | ||
| Decreased Frequency of Somatic Hypermutation and Impaired Affinity Maturation but Intact Germinal Center Formation in Mice Expressing Antisense RNA to DNA Polymerase | Q58424602 | ||
| Antigen-induced apoptotic death of Ly-1 B cells responsible for autoimmune disease in transgenic mice | Q59055762 | ||
| Induction of self-tolerance in mature peripheral B lymphocytes | Q59057608 | ||
| Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice | Q59065295 | ||
| Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes | Q59098044 | ||
| Only DFL16, DSP2, and DQ52 gene families exist in mouse immunoglobulin heavy chain diversity gene loci, of which DFL16 and DSP2 originate from the same primordial DH gene | Q69384748 | ||
| Immunoglobulin heavy chain gene replacement: a mechanism of receptor editing | Q71457193 | ||
| Deletion of the DQ52 element within the Ig heavy chain locus leads to a selective reduction in VDJ recombination and altered D gene usage | Q73401098 | ||
| High affinity rheumatoid factor transgenic B cells are eliminated in normal mice | Q73535779 | ||
| Negative selection at the pre-BCR checkpoint elicited by human mu heavy chains with unusual CDR3 regions | Q73923498 | ||
| Report of a false-positive HIV test result and the potential use of additional tests in establishing HIV serostatus | Q74116917 | ||
| Role of BCR affinity in T cell dependent antibody responses in vivo | Q74139589 | ||
| A transgenic model of autoimmune hemolytic anemia | Q36230807 | ||
| The translesion DNA polymerase zeta plays a major role in Ig and bcl-6 somatic hypermutation. | Q36248087 | ||
| Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies | Q36262823 | ||
| RAG-2-deficient blastocyst complementation: an assay of gene function in lymphocyte development | Q36303172 | ||
| HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. | Q36345558 | ||
| Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation | Q36350233 | ||
| Proapoptotic BH3-only protein Bim is essential for developmentally programmed death of germinal center-derived memory B cells and antibody-forming cells | Q36360433 | ||
| Sequential immunizations with rgp120s from independent isolates of human immunodeficiency virus type 1 induce the preferential expansion of broadly crossreactive B cells | Q36360966 | ||
| Receptor editing: an approach by autoreactive B cells to escape tolerance | Q36361497 | ||
| Receptor editing in self-reactive bone marrow B cells | Q36361578 | ||
| B cells are exquisitely sensitive to central tolerance and receptor editing induced by ultralow affinity, membrane-bound antigen. | Q36367608 | ||
| Autoreactive B cells in the marginal zone that express dual receptors | Q36369869 | ||
| Very low affinity B cells form germinal centers, become memory B cells, and participate in secondary immune responses when higher affinity competition is reduced | Q36370154 | ||
| Positive selection of anti-thy-1 autoreactive B-1 cells and natural serum autoantibody production independent from bone marrow B cell development | Q36370429 | ||
| bcl-2 transgene expression inhibits apoptosis in the germinal center and reveals differences in the selection of memory B cells and bone marrow antibody-forming cells | Q36375912 | ||
| Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape | Q36388754 | ||
| RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. | Q36403678 | ||
| A molecular perspective of CTLA-4 function | Q36427322 | ||
| Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection | Q36444787 | ||
| Antibody polyspecificity and neutralization of HIV-1: a hypothesis | Q36487151 | ||
| Confounding B-cell defences: lessons from a staphylococcal superantigen | Q36488759 | ||
| B-1 B cells: development, selection, natural autoantibody and leukemia | Q36552466 | ||
| Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion | Q36559838 | ||
| Mouse marginal zone B cells harbor specificities similar to human broadly neutralizing HIV antibodies | Q36568026 | ||
| Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. | Q36627503 | ||
| Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. | Q36692987 | ||
| The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection | Q36737159 | ||
| Structural basis for germline antibody recognition of HIV-1 immunogens | Q36739738 | ||
| Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies | Q36750045 | ||
| Anti-HIV B Cell lines as candidate vaccine biosensors | Q36766704 | ||
| Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. | Q36766872 | ||
| Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors | Q36775342 | ||
| Long antibody HCDR3s from HIV-naïve donors presented on a PG9 neutralizing antibody background mediate HIV neutralization | Q36831651 | ||
| Multistep pathogenesis of autoimmune disease. | Q36882282 | ||
| B-cell anergy: from transgenic models to naturally occurring anergic B cells? | Q36887132 | ||
| Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor | Q36888400 | ||
| Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. | Q36895518 | ||
| GANP regulates recruitment of AID to immunoglobulin variable regions by modulating transcription and nucleosome occupancy | Q36906733 | ||
| Understanding B-cell tolerance through the use of immunoglobulin transgenic models | Q36974265 | ||
| Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation | Q36977531 | ||
| The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens | Q37012927 | ||
| Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques | Q37021717 | ||
| Antibody and antiretroviral preexposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model | Q37036786 | ||
| Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10 | Q37049675 | ||
| Sites and stages of autoreactive B cell activation and regulation. | Q37058621 | ||
| Regulation of B-cell development and tolerance by different members of the miR-17∼92 family microRNAs | Q37153957 | ||
| Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10 | Q37171251 | ||
| B cells from knock-in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidates | Q37171260 | ||
| Basal B cell receptor-directed phosphatidylinositol 3-kinase signaling turns off RAGs and promotes B cell-positive selection. | Q37183404 | ||
| Peripheral deletion of self-reactive B cells | Q37209432 | ||
| Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages | Q37221575 | ||
| Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies | Q37246321 | ||
| Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm | Q37247974 | ||
| Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. | Q37252968 | ||
| Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms | Q37278451 | ||
| HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies | Q37293480 | ||
| Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. | Q37318213 | ||
| Optimal immunization cocktails can promote induction of broadly neutralizing Abs against highly mutable pathogens | Q37417794 | ||
| Regulatory T cells in the control of host-microorganism interactions (*). | Q37419387 | ||
| A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges | Q37450695 | ||
| Role of HIV membrane in neutralization by two broadly neutralizing antibodies | Q37453499 | ||
| Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens | Q37456354 | ||
| Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease | Q37600558 | ||
| Modulation of nonneutralizing HIV-1 gp41 responses by an MHC-restricted TH epitope overlapping those of membrane proximal external region broadly neutralizing antibodies | Q37607358 | ||
| Checkpoints in lymphocyte development and autoimmune disease | Q37657051 | ||
| P304 | page(s) | 235-352 | |
| P577 | publication date | 2017-01-01 | |
| P1433 | published in | Advances in Immunology | Q15752932 |
| P1476 | title | Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem | |
| P478 | volume | 134 |
Search more.